https://www.neuritek.com/investors-pr daily 0.75 2026-03-30 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/d585478e-a7eb-42f5-8e48-0f63ff4fa086/brain.png Investors & Media - Abnormal G-protein coupled receptor-mediated anandamide signaling is implicated in PTSD. Breakdown of anandamide in PTSD (left) by FAAH activity versus low FAAH activity healthy non-trauma-exposed (HC) and trauma-exposed controls (TC). https://www.neuritek.com/investors-pr/hijacked-joy-from-illusion-to-truth monthly 0.5 2025-05-13 https://www.neuritek.com/investors-pr/addressing-the-critical-need-for-novel-ptsd-treatments monthly 0.5 2025-03-07 https://www.neuritek.com/home daily 1.0 2026-03-30 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584043607296-KJL07ZDGSMEGRKFAKB33/drew-hays-tGYrlchfObE-unsplash.jpg Home - Experience and rigorous clinical science. We are developing the first mental health treatment specifically for PTSD. This treatment will be efficient in controlling symptoms of PTSD and restoring changes in brain function which develop as a consequence of trauma exposure.. https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584043743834-7RWPPHCI4MH092MF6262/thisisengineering-raeng-04y9odvfymw-unsplash.jpg Home - Innovative research methodologies Neuritek is leveraging 20 years of rigorous basic and clinical research to understand how trauma affects brain and body functions. This lead to the discovery of the body’s own G-protein coupled receptors and its relevance to PTSD. https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584043996983-FO0U4TERMZM2OCHNY44F/giorgio-tomassetti-QCbZ4ASLhM8-unsplash.jpg Home - Highly effective clinical trials. Our clinical trial strategy utilizes a multimodality biomarker strategy, allowing designs of more targeted trials with enhanced sensitivity. We target PTSD subtypes rather than treating PTSD as a unitary disorder, leading to personalized treatments for PTSD. https://www.neuritek.com/leadership daily 0.75 2026-03-30 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/aab39d9a-0b81-4233-81ea-25f875cb6dc7/bill-hapworth.jpg https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/4b776c12-6b90-4451-aa95-1c80a02f9226/profile.jpg https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/62dde23f-8cc8-4261-9023-6a020d0c3551/Allan+Bradley.jpg https://www.neuritek.com/treatment daily 0.75 2026-03-29 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584097106085-Y8F35NJVWSUHOGRSOCSH/doctorexaminesthemriscanofthebrain-1440_0.jpg Our Treatment - Neuritek's treatment approach activates the body's own G-protein coupled receptors. Our advanced research has shown that activating the body's own G-protein coupled system function offers a unique opportunity to treat PTSD and has the potential to improve patient outcomes. https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584123512055-YWO4PD00QM9UO9D9CF55/kelli-mcclintock-wBgAVAGjzFg-unsplash.jpg Our Treatment - PTSD will develop in 20% of trauma survivors, with about 1 in 3 developing chronic PTSD. Between 1.5% to 3.0% of the population have PTSD in a given year, resulting in about 8 million people with PTSD in the United States. It is estimated that worldwide approximatley 354 million war survivors suffer from PTSD, and this number increases significantly considering other causes of severe trauma exposure. Current available treatments include different forms of psychotherapy or medications or their combination. However, patients and clinicians often agree that these treatments are inadequate in addressing the wide range of symptoms in PTSD. Importantly, these treatments often do not control the exaggerated suicide risk, and increased medical risks, resulting in decreased life expectancy in PTSD. https://www.neuritek.com/lead-program daily 0.75 2026-03-29 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1584094604466-6A1L7LESCR42Q2SF2GQ0/90.jpg Lead Program - Although several psychotherapies are available to treat PTSD, novel pharmacotherapy development has lagged and only recently have intensive basic science and clinical studies yielded novel, potentially breakthrough discoveries that have the potential to introduce a new era for trauma survivors with PTSD. https://www.neuritek.com/clinical-trials daily 0.75 2026-03-29 https://www.neuritek.com/contact-us daily 0.75 2024-10-11 https://www.neuritek.com/understanding-ptsd daily 0.75 2021-04-08 https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1598651581919-XBR35SB0CV2TFB6M55RH/neuritek%252Bnews%252Bbackground.jpg Understanding PTSD - What is PTSD? Post-traumatic stress disorder, or PTSD, is characterized as a psychiatric disorder affecting individuals who experienced and/or witnessed a traumatic event (1). It continues to occur even after the event has passed. Such events include but are not limited to: war, terrorist acts, rape / sexual assault, physical assault, domestic violence, natural disasters, and epidemics, such as Covid-19 (1). PTSD can interfere with the overall quality of life and interpersonal relations, can contribute to the development of other medical problems (e.g. heart disease), and can negatively impact psychosocial functioning and the ability to work (2). https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1598739627972-ZVVCE5R03SFX6DAWV934/banner-iStock-958457392.jpg Understanding PTSD - Who can get PTSD? Any person who was exposed to a traumatic event can develop PTSD. However, not everyone who has experienced a severe trauma develops PTSD. Approximately 1 in 11 people are diagnosed with PTSD in their lifetime (1). https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1598671654962-JQIQW9O2Y0PY3F4RUEHD/Screen+Shot+2020-08-28+at+10.43.58+PM.png Understanding PTSD - What are the symptoms? Re-experiencing the traumatic event through nightmares and/or flashbacks Avoidance of the traumatic event, as well as memories, situations & people associated with it Recurring perceptions of a threat stemming from changes in arousal and activity Changes in overall mood Specific PTSD symptoms can vary from individual to individual, requiring a personalized treatment approach (3). https://images.squarespace-cdn.com/content/v1/5e6a1873d5d8d73f8c01c00f/1598734483907-VM5PYBX1JCZKLSKNC1SJ/Screen%2BShot%2B2020-08-28%2Bat%2B11.15.45%2BPM.jpg Understanding PTSD - How can Neuritek help patients with PTSD? Current PTSD treatments do not work for all patients. Many patients continue to experience symptoms of PTSD although they engaged in psychological and medication treatments (2). This is where we, Neuritek Therapeutics, come in. We are committed to develop a novel, bio-mechanism based treatment for PTSD in order to improve patient outcomes. https://www.neuritek.com/news01 daily 0.75 2021-04-05